Clinical trail phases
Clinical Trials
Our department is currently actively participating in the following clinical trials:
Neoadjuvant
- Alliance A011202
- PI: Dr. Robert Gabordi
- A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
- NSABP B-51/RTOG 1304
- PI: Dr. Robert Gabordi
- A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Adjuvant
- NRG-BR003
- PI: Dr. Bruce Hough
- A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node-Negative Triple-Negative Invasive Breast Cancer
Non-Therapeutic
- Agendia- Impact
- PI: Dr. Robert Gabordi
- Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry (IMPACt)
Treatment Resistant Disease
- NCI-MATCH
- PI: Dr. Bruce Hough
- Molecular Analysis for Therapy Choice (MATCH)
- Arbor-Pharmaceuticals- Vigilant
- PI: Dr. Samy Elhammady
- Protocol AR22.001- Vigilant Observation of Gliadel WAfer ImplaNT (Vigilant) Registry to Collect Information on the Safety and Efficacy of Gliadel®